The drug, called Journavx (suzetrigine) and manufactured by biotech company Vertex Pharmaceuticals, is a non-opioid painkiller, which doesn’t have addictive properties, unlike opioids often used ...

The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx. “A new non-opioid analgesic ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults. The active ingredient in Journavx is suzetrigine ...

Suzetrigine is the first medication in its class to gain federal approval in over 20 years The approval of Journavx is particularly significant for Florida, where opioid addiction has become a ...

About JOURNAVX™ (suzetrigine) JOURNAVX (suzetrigine) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels.

Journavx (suzetrigine), made by Vertex, is the "first and only approved non-opioid oral pain signal inhibitor," according to a press release from the Massachusetts-based company. The new drug is ...

That is because the drug, suzetrigine, made by Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside the brain, blocking pain signals. It cannot get into the brain.

Suzetrigine is the first selective NaV1.8 pain signal inhibitor approved for acute pain, offering a non-opioid alternative amid the opioid crisis. Clinical trials demonstrated significant efficacy ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years. “Today’s approval is an important public health ...

Suzetrigine, sold as Journavx, is administered twice daily in 50-milligram oral tablets to treat moderate and severe acute pain. Clinical trials showed that the medication dampened pain as ...